Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
NCT03370302 · Calithera Biosciences, Inc · PHASE1 · terminated · last registry update 2023-02-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “More favorable safety profile was observed in QD schedule, therefore further enrollment in QW schedule was terminated.” | – | Registry record, Calithera Biosciences, Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-12Results posted on the registry: Dana-Farber Cancer Institute, MLN0128 (NCT02244463)
- 2023-10-17Also stopped (terminated): National Cancer Institute (NCI), Navitoclax + Vistusertib (NCT03366103)
- 2023-10-04Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Sapanisertib (NCT02142803)
- 2023-09-14Results posted on the registry: Genentech, Inc., Abiraterone + Apitolisib (NCT01485861)
- 2023-05-09Results posted on the registry: Joyce O'Shaughnessy, Tak-228 & Tak-117 + Cisplatin & Nab Paclitaxel (NCT03193853)
- 2023-05-03Results posted on the registry: National Cancer Institute (NCI), Navitoclax + Vistusertib (NCT03366103)
- 2022-10-14Also stopped (terminated): Fox Chase Cancer Center, TAK-228 (NCT02987959)
- 2022-09-30Also stopped (withdrawn): Luke, Jason, MD, navoximod + NLG802 (indoximod Prodrug) (NCT05469490)
- 2022-09-27Results posted on the registry: NewLink Genetics Corporation, Pembrolizumab + Nivolumab (NCT03301636)
- 2022-09-27Also stopped (terminated): NewLink Genetics Corporation, Pembrolizumab + Nivolumab (NCT03301636)
- 2022-08-23Also stopped (terminated): National Cancer Institute (NCI), Pazopanib + Pazopanib Hydrochloride (NCT02601209)
- 2022-08-16Phase 3 first posted: Celcuity Inc, Gedatolisib + Palbociclib (NCT05501886)
- 2022-07-26Also stopped (terminated): Kathy Miller, MLN0128 + MLN0128 (RP2D) (NCT02575339)
- 2022-05-27Also stopped (withdrawn): M.D. Anderson Cancer Center, Nivolumab + Sapanisertib (NCT05022394)
- 2022-05-24Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02484430)
- 2022-04-06Also stopped (terminated): NewLink Genetics Corporation, Docetaxel + Tergenpumatucel-L (NCT02460367)
- 2022-04-05Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02893930)
- 2022-04-05Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02417701)
- 2022-03-31Results posted on the registry: Kathy Miller, MLN0128 + MLN0128 (RP2D) (NCT02575339)
- 2022-02-24Results posted on the registry: Bradley A. McGregor, MD, TAK-228 (NCT03097328)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision